Sequent is currently trading at Rs. 163.00, up by 11.70 points or 7.73% from its previous closing of Rs. 151.30 on the BSE.
The scrip opened at Rs. 172.00 and has touched a high and low of Rs. 172.00 and Rs. 154.50 respectively. So far 3,937 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 257.00 on 20-Dec-2012 and a 52 week low of Rs. 74.05 on 04-Jun-2012.
Last one week high and low of the scrip stood at Rs. 170.00 and Rs. 145.00 respectively. The current market cap of the company is Rs. 627 crore.
The promoters holding in the company stood at 60.47% while Institutions and Non-Institutions held 0.17% and 39.36% respectively.
Sequent Scientific (Sequent) has received an US FDA approval for its API drug manufacturing facility at Mangalore, Karnataka. The company’s Mangalore facility is ISO 9001 certified for Quality Management systems and ISO 14000 certified for Environment Management systems. This state-of-the-art facility engaged in the development and manufacture of APIs and API Intermediaries.
This facility has earlier received quality approval from TGA, Australia and certified by World Health Organisation, Geneva under its Prequalification's of Medicines Programme.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |